Abstract
BACKGROUND: Patients initiating highly emetic chemotherapy (HEC) are at a 90% risk of chemotherapy-induced nausea and vomiting (CINV). Despite guideline-concordant antiemetic prescribing preventing CINV in up to 80% of patients, studies suggest that guideline-concordant antiemetic regimen use by patients initiating HEC is sub-optimal. However, these studies have been limited to single-site or single-cancer type with limited generalizability. The objective of this study was to describe antiemetic fill regimens and to assess predictors of underuse in the USA.
METHODS: Our study population was adult patients under the age of 65 with cancer initiating intravenous HEC between 2013 and 2015 with employer-sponsored insurance in the IBM Watson/Truven MarketScan Commercial Claims database (N = 31,923). Descriptive statistics were used to explain antiemetic prescribing patterns, including antiemetic underuse. Modified Poisson regression was used to identify factors associated with antiemetic underuse.
RESULTS: Among individuals initiating HEC, 49% underused guideline-concordant antiemetics. Most classified as under-using lacked an NK1 fill. While dexamethasone and 5HT3A uptake was over 80%, olanzapine use was minimal. Having lower generosity for prescription and medical benefits (paying more versus less than 20% out-of-pocket) increased the underuse risk by 3% and 4% (RR,1.03; 95% CI,1.01-1.05; P = 0.01 and RR,1.04; CI, 1.00-1.09; P = 0.03), respectively. Additionally, compared to receiving chemotherapy in the physician office setting, patients were at a 28% (RR, 1.28; 95% CI, 1.25-1.30; P < 0.0001) higher underuse risk in the outpatient hospital setting.
CONCLUSION: Antiemetic underuse is high in patients initiating HEC, potentially leading to avoidable CINV events. We found that insurance generosity has a minimal effect on antiemetic guideline concordance in this population, suggesting discordance may be the result of site of care as well as gaps in provider knowledge or accountability.
Original language | English (US) |
---|---|
Pages (from-to) | 4525-4534 |
Number of pages | 10 |
Journal | Supportive Care in Cancer |
Volume | 27 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2019 |
Bibliographical note
Publisher Copyright:© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Keywords
- Antiemetics
- Chemotherapy-induced nausea and vomiting
- Claims data
- Clinical guidelines
- Value-based care
- Antineoplastic Agents/administration & dosage
- Antiemetics/administration & dosage
- Nausea/chemically induced
- Humans
- Middle Aged
- Neoplasms/drug therapy
- Male
- Young Adult
- Vomiting/chemically induced
- Guideline Adherence
- Adolescent
- Adult
- Female
- Insurance, Health
- Databases, Factual
PubMed: MeSH publication types
- Journal Article